Miconazole

證據等級: L5

預測適應症: 1 個

Miconazole: From Fungal Infections to Acne

One-Sentence Summary

Miconazole is an antifungal agent of the imidazole class, originally used to treat fungal infections. The TxGNN model predicts it may be effective for Acne, but this direction is currently supported by only 1 clinical trial (indirect relevance) and 4 publications, none of which are direct RCTs of miconazole in acne patients.

Quick Overview

Item	Content
Original Indication	Fungal infections (imidazole/azole antifungal class)
Predicted New Indication	Acne
TxGNN Prediction Score	99.54%
Evidence Level	L3
US Market Status	Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, miconazole is part of the imidazole/azole antifungal class; its efficacy in fungal skin infections has been established, and mechanistically it may be applicable to acne.

Miconazole inhibits lanosterol 14-α-demethylase, a mechanism traditionally associated with antifungal activity but that also confers direct antibacterial activity. In vitro data (PMID 20045949) show azole antifungal agents, including miconazole, are active against Propionibacterium (Cutibacterium) acnes, the bacterium implicated in acne pathogenesis. This suggests a plausible dual mechanism: (1) reduction of P. acnes burden through direct antibacterial action, and (2) treatment of Malassezia (Pityrosporum) folliculitis, a condition frequently misdiagnosed as acne vulgaris and for which miconazole has established antifungal efficacy (PMID 8593718).

This mechanistic rationale is biologically plausible but remains preclinical/in vitro in nature — no direct clinical evidence yet confirms miconazole’s efficacy against acne vulgaris itself, as distinct from its efficacy against Malassezia folliculitis (a clinical mimic of acne).

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01244256	Phase 2/3	Suspended	80	Evaluated a combination cream (beclomethasone + gentamicin + clotrimazole, not miconazole) in patients with contaminated dermatosis/acne-like lesions. Relevance graded C: the tested drug is clotrimazole (a different azole), the trial was suspended, and enrollment figures are inconsistent with registry data — only indirectly supports the azole-class mechanistic rationale, not miconazole specifically.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
15536660	2004	Controlled clinical trial (split-face, n=35)	Skin Research and Technology	Assessed catamenial acne management; notes oral contraceptives may help without fully clearing skin lesions (does not directly test miconazole).
18627330	2008	Review	Expert Opinion on Pharmacotherapy	Reviews the multifaceted effects of miconazole nitrate, a “time-honored” imidazole antifungal, on various skin disorders.
8593718	1995	Case series / therapeutic trial	Clinical and Experimental Dermatology	62 patients with Pityrosporum folliculitis — frequently misdiagnosed as acne vulgaris — evaluated and treated; supports miconazole’s role in an acne-mimicking condition.
20045949	2010	In vitro study	Biological & Pharmaceutical Bulletin	Azole antifungal agents, including miconazole, tested in vitro against P. acnes isolates from acne vulgaris patients, showing anti-bacterial activity.

US Market Information

Miconazole is currently not marketed under any NDA in the available Taiwan/US regulatory data (0 licenses on record). No product or dosage form information is available in this evidence pack.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic rationale (in vitro anti-P. acnes activity and treatment of the acne-mimicking Malassezia folliculitis) is plausible, but no direct clinical trial or RCT has tested miconazole in acne vulgaris — the only registered trial actually studied a different drug (clotrimazole) and was suspended. Combined with a blocking data gap on TFDA safety information and the drug’s current unmarketed status, evidence is insufficient to proceed.

To proceed, the following is needed:

TFDA label warnings/contraindications (blocking gap, required for S1 safety screening)
Confirmed mechanism of action data from DrugBank
A direct clinical trial of miconazole (not a related azole) in acne vulgaris patients
Clarification of whether the target indication is acne vulgaris specifically or Malassezia folliculitis (often conflated in the literature)
Topical formulation/route data if pursuing dermatologic development
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.